Área de Gestión Clínica Medicina Interna, Hospital Universitario Central de Asturias, Grupo de Microbiología Traslacional, Instituto de Investigación del Principado de Asturias, Asturias, Spain.
Departamento de Microbiología, Hospital Clínic, Instituto de Salud Global Barcelona, Hospital Clínic, Universidad de Barcelona, Barcelona, Spain.
Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jun-Jul;41(6):329-334. doi: 10.1016/j.eimce.2022.08.006. Epub 2022 Aug 12.
The generalization of treatment with dexamethasone or other immunosuppressants in patients with SARS-CoV-2 infection may increase the risk of occurrence of severe forms of strongyloidiasis. A nationwide survey was conducted to better understand the diagnostic and therapeutic situation of strongyloidiasis in SARS-CoV-2 co-infected patients in Spain.
A survey was designed and sent to all SEIMC members during February and March 2021. Responses were exported for computer processing to Microsoft Excel 2017 and statistically processed with the free software PSPP.
189 responses were received, of which 121 (64%) were selected for further processing. Eighty-four centers (69.5%) had no specific strongyloidiasis screening protocol. Forty-two centers (34.7%) had serological techniques available in their laboratories and the rest were sent to a reference laboratory. Only 22 centers (18%) screened for strongyloidiasis in SARS-CoV-2 infected patients. A total of 227 cases of strongyloidiasis were diagnosed in patients with SARS-CoV-2 infection. In four cases patients developed a massive hyperinfestation syndrome leading to the death of one patient.
COVID-19 has highlighted the need to unify screening and treatment protocols for imported pathologies such as strongyloidiosis. Efforts to disseminate knowledge are needed to ensure that this potentially fatal disease is adequately treated in patients with the highest risk of complications, such as those with COVID-19.
在 SARS-CoV-2 感染患者中广泛使用地塞米松或其他免疫抑制剂可能会增加发生严重强虫病的风险。进行了一项全国性调查，以更好地了解西班牙 SARS-CoV-2 合并感染患者中强虫病的诊断和治疗情况。
在 2021 年 2 月和 3 月期间，设计并向所有 SEIMC 成员发送了一项调查。将回复导出到 Microsoft Excel 2017 中进行计算机处理，并使用免费软件 PSPP 进行统计处理。
共收到 189 份回复，其中 121 份（64%）被选中进行进一步处理。84 个中心（69.5%）没有特定的强虫病筛查方案。42 个中心（34.7%）在其实验室中具有血清学技术，其余的则被送到参考实验室。只有 22 个中心（18%）对 SARS-CoV-2 感染患者进行了强虫病筛查。在 SARS-CoV-2 感染患者中诊断出总共 227 例强虫病。在 4 例患者中，发生了大规模的过度感染综合征，导致一名患者死亡。
COVID-19 突出表明需要统一筛查和治疗进口性疾病（如强虫病）的方案。需要努力传播知识，以确保在 COVID-19 等并发症风险最高的患者中充分治疗这种潜在致命疾病。
